NeoImmuneTech’s NT-I7 (efineptakin alfa) Receives the US FDA Orphan Drug Designation for the Treatment of Glioblastoma Multiforme
Shots:
- The US FDA has granted ODD to NT-I7 & bolsters NeoImmuneTech's determination to advance the clinical development of NT-I7 as new therapy for Glioblastoma Multiforme
- In the P-I & II trial, NT-I7 showed promise for expanding T cells in all subsets, enhancing the immune system, and extending the anti-tumor response in patients with GBM and other solid tumors while the preliminary data from (the NIT-107) study showed favorable trends of PFS and OS in NT-I7 treated HGG patients after chemoradiotherapy
- NT-I7 is being evaluated in multiple trials for solid tumors and as a vaccine adjuvant. Additionally, studies in additional solid tumors, hematologic malignancies, and other immunology-related indications are being planned
Ref: PRNewswire | Image: NeoImmuneTech
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
